Company intelligence / Profile preview

Medical Union Pharmaceuticals

Cairo, Cairo Governorate, Egypt

Ownership: Private
Employees: ~2357
Development stage: Other

Overview

Medical Union Pharmaceuticals (MUP) manufactures and markets a wide range of branded and non-branded generic medicines, including biosimilars and branded generics. Its portfolio covers small molecules, biologics (notably human insulin), and antibiotics, with ongoing operations in over 40 countries, mainly at commercial scale. No late-stage novel drugs or platform-based R&D is reported; the focus is on regional and international distribution of established pharmaceuticals, including their successful launch of human insulin after acquiring Eli Lilly's local insulin factory.

Therapeutic areas: Infectious DiseasesEndocrinologyGastroenterology
Modalities: Small moleculeBiologicProteinPeptides
Industry: Contract Manufacturing Organization

Beyond the preview

Go deeper on Medical Union Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Medical Union Pharmaceuticals.

Explore the full profile